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We have previously showed that, despite the significant reduc-
tion of transplant-related mortality (TRM) achieved by using
reduced intensity conditioning (RIC), relapse continues to be a ma-
jor cause of failure, especially in advanced-stage hematologic ma-
lignancies. In order to improve relapse-free survival in the setting
of reduced intensity sibling donor transplants for advanced hema-
tologic malignancies, our group has tested a modified Fludara-
bine/Busulfan RIC regimen (fludarabine 150 mg/m2 IV, busulfan
6 mg/kg IV, total lymphoid irradiation 2 Gy) with a rapid post-
transplant immunosuppression (IS) taper (start day 28, finish day
63) in a prospective single arm phase II study. The rapid taper
was intended to facilitate a GVL effect that hopefully would trans-
late into improved DFS. Patients without progression who did not
develop GVHD by d100 received planned donor lymphocyte infu-
sion (DLI) 5  107 CD31/kg. 45 pts (median f/u 918d; range 100–
1835d) have been treated between 8/2003- 2/2008. The median age
was 56y (2–67y); 19 (42%) failed previous autologous HCT. Five
patients received DLI. Forty patients received HSC from 6/6
HLA matched and 5 from 5/6 HLA matched related donors. Rapid
tacrolimus taper reliably induced GVHD grade 2–4 in the study
population (73 6 6%) by day 100 at a median of 46d (range, 18–
98d). Extensive chronic GVHD developed in 6567% of patients.
GVHD in this context was rarely fatal (7 GVHD-related deaths) re-
sulting in 2-year NRM of 24 6 7%. Outcomes were analyzed for
the whole group and by stratification according to risk of relapse af-
ter non-myeloablative HSCT.Stratification of the Study Patients According to the Esti-
mated Risk of Relapse After NMA HSCT (1)
High/Standard-risk disease n528 Low-risk disease n517
AML (de novo) 4 Follicular lymphoma, low grade 4
AML (secondary) 3 MAntle cell lymphoma 4
AML (treatment-related) 2 DLBCL/t-DLBCL, CR 3
MDS 6 NHL/AITL, CR 1
CML-BC 1 MM, CR 5
Ph1ALL, CR2 1
Hodgkin’s disease, refractory 4
MM, refractory 5
t-DLBCL, refractory 1
CLL, refractory 1
(1)-kahl, c., et al. Bood 2007; 110:7 2744-48The 2-year OS and PFS for all pts was 38617% and 3567% re-
spectively, with superior PFS seen in low risk vs high/standard
risk pts (526 13% vs 2668% p 5 0.03). A higher cumulative in-
cidence of progression in high/standard risk pts (6369% vs 0%,
p5 0.0001) accounted for most of the difference in survival. How-
ever, when compared to similar risk group pts in our prior trial
(Levine, et al, BBMT 2003) that utilized identical conditioning,
but a conventional IS taper, there were no differences in PFS for
low risk (58% vs 50%, p 5 NS) or high risk pts (29% vs 23%,
p 5 NS). TRM rates were similar in both trials (32% vs 24%,
p 5NS). Thus, while a rapid IS taper in this RIC setting induces
GVHD that is usually non-lethal, the desired GVL effect did not
manifest itself in terms of improvements in PFS for low or high
risk pts.
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Background: Patients undergoing hematopoietic stem cell or
bone marrow transplants (HSC/BMTs) are at an increased risk of
contracting invasive fungal infections (IFIs). Data on the economic
burden of these infections are sparse.Methods: This retrospective matched cohort study used data
from the 2004 and 2005 Healthcare Cost and Utilization Pro-
ject Nationwide Inpatient Sample (HCUP-NIS) to assess the
excess mortality, lengths of stay, and costs of IFIs in HSC/
BMT recipients. Patients were selected for the IFI cohort if
they had ICD-9-CM codes indicating an HSC/BMT procedure
and an IFI during their hospital stay. Patients were matched to
controls (transplant recipients who had no diagnosis of IFI)
based on age (within 10 years), sex, hospital region, hospital
type, year in hospital (2004 or 2005), and type of transplant (al-
logeneic HSC/BMT, or autologous HSC/BMT). Analyses of
mortality, lengths of stay, and costs were reported overall and
by type of transplant.
Results: In 2004 and 2005, 4,661 patients received an HSC or
BMT. Of these, 111 (2.4%) had a diagnosis of an IFI in hospi-
tal. Almost all IFI patients (98%) could be matched to controls.
After matching, the mean (6SD) age was 37.8 (621.6) years,
62% of patients were male, and patients were predominately
white. Common comorbidities among patients with an HSC/
BMT and an IFI included fluid and electrolyte disorders
(46.8%), hypertension (16.5%), and coagulopathy (13.8%). As-
pergillosis was the most common type of mycosis followed by
candidiasis. Overall, IFIs in HSC/BMT recipients were associ-
ated with a 6-fold increase in mortality (23.2% among patients
with IFIs vs 3.8% among patients without IFIs), excess mean
(6SD) lengths of stay of 16.2 (65.0) days, and excess mean
(6SD) costs of $51,655 (6$12,399) per patient. Patients with
allogeneic HSC/BMT had higher excess mortality and excess
lengths of stay but lower excess costs than patients with autol-
ogous HSC/BMT.
Conclusions: The excess burden of IFIs among HSC/BMT re-
cipients is high. Improved efforts to prevent these infections may
yield both clinical and economic benefits.14
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This retrospective analysis concerned 374 patients (pts) who un-
derwent an allo-HSCT for CLL reported to the EBMT registry.
There were 282 M and 92 F, median age 53 years (24–69). The in-
terval diag-transp. was 53 months (3–308). Forty five pts (12%)
have received a previous HSCT. At transplant, 302 among 323
evaluated pts had a good performance status (PS) (93%), 51 pts
were in CR (14%), 163 in PR (45.5%), 39 in SD (11.5%) and
105 in PD (29%) among 353 evaluated pts. As conditioning, 292
pts received a standard (std) one and 82 RIC; 314 pts received
PBSC, 55 BM and 5 cord blood cells from 202 HLA siblings
(Sib), 2 mismatched related donors and 170 unrelated donors
(UD). There were 136 (36%) sex-mismatched, 150 pairs (40%)
had an ABO incomp. (61 min., 99 maj.). There were 359 pts en-
grafted, 201 AGVHD (gr I: 76, gr II : 79 , gr III: 30 and gr
IV:16) and 15 cGVHD (75 lim., 78 ext.). At day 100, the cumula-
tive incidence (CI) of AGVHD for the total population was 17%
(13–22) for gr I, 31% (26–36) for gr $ II. [Sib: 19% (13–25) gr
I and 27% (21–34) gr $ II; UD: 16% (9–22) gr I and 38%
(29–47) gr $ II].
8 Oral PresentationsTable 1. Cumulative incidence of AGVHD, NRM and Relapse
according to HLA typing and kind of conditioning
RIC Std11HLA siblings
AGVHD (D100) Gr I 15% [9-20,5] 34% [19-49]
Gr II 15% [9-21,4] 9,5% [7-49]
Gr III-IV 11% [6-16] 12% [2-22]
NRM at 1 year 8,4% [12-25] 23% [11-35.6]
Relapse at 1 year 13% [8 -19] 6% [0-14]Unrelated Donors
AGVHD (D100) Gr I 13% [6-20] 22% [4-39]
Gr II 22% [13-30] 26% [7,5-45]
Gr III-IV 14% [7-21] 22% [4-39]
NRM at 1 year 24% [16-32] 36% [17-55]
Relapse at 1 year 16% [9-23] 4% [0-12]The CI of lim. and ext. cGVHD at 1 yr, were 15 % (6–24) and
29.5% (18–41) for Std; 18.6 (13–24) and 18% (13–23) for RIC re-
spectively. With a median follow up of 38 months, the 3 and 5-yr
OS and DFS were 56% (51–62) and 47.4 % (42–53); 49 % (43–56)
and 42% (36–48.5) respectively.We observed a significant difference
concerning 5-yr OS according to the pretransplant disease status
[CR: 73% (60–89), PR: 57% (48–68) and PD: 35% (26–46)]
(p\0.00001).There was no significant difference between std and
RIC in term of OS with 52.4 % (42–66) and 47% (40–55.5) respec-
tively (p 5 0.44) [Std and RIC Sib: 51% (37–70) and 56% (47–67);
Std and RIC UD: 60% (44–83) and 40% (29–55) respectively].
The multivariate analysis showed a significant impact of 3 factors
on OS: age: HR 5 1.061 (1.02–1.10) p\0.0001, gender: HR 5
2.29 (1.02–5.11) p 5 0.04 and PS: HR 5 3.15 (1.40–7.10) p 5
0.005.The CI of non-relapse and relapse mortality (NRM and
RM) at 3 months and 1 yr were: 10 % (7–13), 5% (3–7) and 24%
(19–28), 15% (12–19) respectively [Std:23 % (11–35.6), 6% (0–14)
1 year; RIC: 22.5% (17.5–27), 18% (13–22) at 1 year]. We showed
a high percentage of long-termOS after HSCT for CLL either after
Std or RIC without any difference between the 2 groups except
for the AGVHD and an important impact of disease status
pretransplant; age, PS and sex-matching on the global OS.15
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Host antigen presenting cells have been shown to play an impor-
tant role in triggering graft-versus-host disease (GVHD) in animal
models of allogeneic hematopoietic cell transplantation (HCT).
To determine whether kinetics of skin LC-chimerism, as assesses
by combined XY-FISH and Langerin-immunohistochemistry
among recipients of sex-mismatched grafts, are influenced by condi-
tioning-intensity in human patients, we prospectively obtained skin
biopsies before and after myeloablative (MA) and nonmyeloablative
(NMA) HCT. The conversion-kinetics of LC-chimerism were then
compared to those of dendritic cells (DC) in peripheral blood (pB)
and bone marrow (BM), and CD3 T-cells and CD56 NK-cells in
pB. Of the 28 patients analyzed, 11 had received MA conditioning
(12 Gy total body irradiation [TBI] and cyclophosphamide, n 5 5;
treosulfan and fludarabine, n 5 4; busulfan and cyclophosphamide,
n 5 2) and 17 had received NMA conditioning (2 Gy TBI
alone, n 5 2; 2 Gy TBI and fludarabine, n 5 13; 3 Gy TBI and flu-
darabine, n 5 2). All patients were transplanted for hematologic
malignancies and were given PBSC (n 5 27) or BM grafts (n 5 1)
from HLA-matched related (n 5 12) or unrelated (n 5 16) donors.
The median degree of day-28 donor LC-chimerism among all pa-
tients was 13% (range, 0–100%), which corresponded to 91%
(range, 0–100%) and 8% (0–100%) for patients given MA and
NMA conditioning, respectively (p 5 0.0008).Level of donor Langerhans cell (LC), dendritic cell (DC), T-cell
andNK-cell chimerismon day-28 after transplant according to
conditioning-intensity and tissue-compartment
Conditioning IntensityMyeloablative (n511) Non-Myeloablative (n517)% Median donor chimerism (range)Skin-LC 91 (0-100) 8 (0-100)
pB-DC 100 (90-100) 100 (93-100)
BM-DC 100 (82-100) 100 (96-100)
pB-T-cell 99 (85-100) 78 (57-100)
pB-NK-cell Not determined 100 (55-100)pB, peripheral blood; BM, bone marrow.
Only 3 of the 17 patients (18%) with NMA conditioning had day-
28 donor LC-chimerism of .50%, which corresponded to 9 of 11
patients (82%) withMA conditioning. Two of the 3NMA transplant
recipients with.50% LC-chimerism were the only patients given 3
Gy TBI instead of the standard 2 Gy TBI. The median degrees of
day-28 donor chimerism for the other cell populations examined
were as follows: pB-DC, 100% (range, 93–100%); BM-DC, 96%
(range, 96–100%); pB-T-cells, 78% (range, 57–100%); and pB-
NK-cells, 100% (55–100%). Skin LC-chimerism levels did not cor-
relate with those of blood cell populations. In conclusion, although
circulating DCs and lymphocytes were largely donor-derived by
day-28 after transplant regardless of conditioning-intensity, LCs re-
mained predominantly host-derived after NMA conditioning. Lon-
ger follow-up is needed to determine whether kinetics of DC/LC-
chimerism may predict GVHD-characteristics and GVT-effects,
information that could be used for individualizing immunosuppres-
sive therapy and thereby lowering the toxicity of allogeneic HCT.16
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An argument can be made that a real or perceived conflict-of-
interest may arise in the situation where the same physician is
responsible for the care of two individuals whose care is interdepen-
dent. Care of donors and recipients in tissue transplantation may
represent an example. In hematopoietic stem cell transplantation
(HSCT) from unrelated donors facilitated by the National Marrow
Donor Program and in the setting of solid organ transplantation
from living donors, the standard-of-care is for donors and recipi-
ents to be under the care of separate physicians in order to provide
unbiased care and eliminate the potential for a conflict-of-interest.
However, the practice patterns of evaluation and care of related do-
nors and recipients at centers performing HSCT are unknown. Ac-
cordingly, a practice pattern survey of transplant centers in the
United States reporting to the CIBMTRwas conducted by the Do-
nor Health and Safety Committee between December 2007 and
July 2008. The survey was administered as an online survey tool
sent to the center medical directors. The survey focused primarily
on determining the type of provider involved in medical clearance,
informed consent and medical management of the donor and the
relationship of that provider to the recipient. Of 258 centers sur-
veyed, 87 centers responded (33%). The median number of related
donor transplants per year at responding institutions was 16 (range:
1–115); the median total number of transplants per year was 70 (5–
450). As shown in the table, transplant physicians in no less than
70% of centers were involved in overlapping care of the donor
and the recipient during the donor evaluation, clearance and
